Evogene (NASDAQ:EVGN) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Evogene (NASDAQ:EVGN) in a research report issued on Sunday. The firm set a “sell” rating on the biotechnology company’s stock.

Evogene Trading Down 3.4 %

Shares of NASDAQ:EVGN opened at $1.41 on Friday. The stock has a market capitalization of $7.56 million, a P/E ratio of -0.32 and a beta of 1.29. The business has a 50-day moving average price of $1.59 and a two-hundred day moving average price of $2.13. Evogene has a 1-year low of $1.20 and a 1-year high of $10.40.

Hedge Funds Weigh In On Evogene

An institutional investor recently bought a new position in Evogene stock. Citadel Advisors LLC bought a new position in shares of Evogene Ltd. (NASDAQ:EVGN) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 15,891 shares of the biotechnology company’s stock, valued at approximately $30,000. Citadel Advisors LLC owned approximately 0.30% of Evogene as of its most recent filing with the Securities and Exchange Commission. Hedge funds and other institutional investors own 10.40% of the company’s stock.

Evogene Company Profile

Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The company operates through three segments: Agriculture, Human Health, and Industrial Applications.